User:Mr. Ibrahem/Linagliptin

Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat diabetes mellitus type 2. It is generally less preferred than metformin and sulfonylureas as an initial treatment. It is used together with exercise and diet. It is not recommended in type 1 diabetes. It is taken by mouth.

Common side effects include inflammation of the nose and throat. Serious side effects may include angioedema, pancreatitis, joint pain. Use in pregnancy and breastfeeding is not recommended. Linagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitors). It works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.

Linagliptin was approved for medical use in the United States in 2011. A month supply in the United Kingdom costs the NHS about £33 as of 2019. In the United States the wholesale cost of this amount is about 391 USD. In 2017, it was the 200th most commonly prescribed medication in the United States, with more than two million prescriptions.